Life Science Services

(Internal silos combined with bureaucracy = customs limbo putting patients’ lives at risk.)

By Rui Manuel Teixeira

#GOATConsultants in suit shaking hands with lab scientist in customs office, resolving blocked biotech medicine shipment.
Biotech customs compliance done right: €800K in medicine saved, patients protected.

Delivering Outcomes That Move Millions

Free consultation call-to-action banner – Get Your Free Consultation Today – Click Here to Start Winning

The Challenge

A U.S.-based biotech, operating in Europe through its Swiss subsidiary, launched a life-saving treatment in France via an Early Access Program (EAP/AAP).

Due to internal miscommunication, a critical €800K shipment of refrigerated medicine was blocked at French customs

  • Incorrect licensees stated
  • Wrong Importer of Record

The EAP was on the verge of collapse, and patients’ access to vital treatment was jeopardized because of regulatory non-compliance.

Our Intervention

We acted fast and decisively:

  • Secured a “free zone for goods in transit” to safeguard the shipment while correcting documentation.
  • Finalized import authorization with the French regulator (ANSM) under the correct representative.
  • Enabled direct representation rights for customs clearance.
  • Activated a reverse charge VAT mechanism, importing goods VAT-free.

For more information on biotech customs compliance, consult the EU Customs Union, the EAP Overview on EMA and the OECD Trade Facilitation in Healthcare websites.

The Outcome

  1. €800K of life-saving medicine saved from destruction 
  2. No penalties, no delays
  3. Patients received critical treatment 
  4. EAP program continued without interruption 
  5. Future shipments now bulletproof for compliance
Shipping Investigational Medicinal Products (IMPs) for clinical trials in Europe is a critical yet complex process. IMPs are unapproved drugs used in clinical trials or Early Access Programs (EAPs) for patients with unmet medical needs. Because IMPs are not approved by regulatory agencies like the FDA or EMA, shipping them across borders involves navigating a maze of customs regulations, value-added taxes (VAT), and specific local requirements. In this guide, we outline how biotechs and biopharmas can avoid common mistakes when shipping IMPs to Europe.

Shipping Investigational Medicinal Products (IMPs) in Europe is high-stakes. One misstep can trigger costly delays.

Learn how to stay compliant and avoid common pitfalls in our full guide.


🐐#GOATConsultants™-Level Insights:

When internal silos and bureaucracy threaten both business and patient lives, clarity and execution make all the difference.

We deliver results that matter. Because in biotech, it’s not just about money. It’s about saving lives.


CTA banner – This is why life sciences companies trust us – Book Your Free Consultation Now

Enjoy more Success Stories: